OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

Market Cap	107.64B +3.8%
Revenue (ttm)	91.62B +11.8%
Net Income	12.70B +39.8%
EPS	796.25 +33.9%
Shares Out	17.65M
PE Ratio	7.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	525,177
Open	5,850.00
Previous Close	6,100.00
Day's Range	5,260.00 - 5,940.00
52-Week Range	5,390.00 - 20,750.00
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 131030

Financial Performance

In 2025, OPTUS Pharmaceutical's revenue was 87.16 billion, an increase of 6.42% compared to the previous year's 81.90 billion. Earnings were 11.36 billion, an increase of 10.18%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 21, 2026

Data Sources Report a data error